Source link : https://www.newshealth.biz/health-news/combined-icodec-semaglutide-looks-good-compared-to-insulin/
Novo-Nordisk’s fixed-ratio once-weekly combined basal insulin icodec and semaglutide product (IcoSema) was noninferior in A1c-lowering to daily injected glargine U100 plus aspart insulins in people with type 2 diabetes, according to topline trial data released by the company. In phase 3a data from the 52-week open-label randomized COMBINE 3 clinical trial, once-weekly injected IcoSema was […]
Author : News Health
Publish date : 2024-01-10 11:49:01
Copyright for syndicated content belongs to the linked Source.